Good afternoon. My name is Josh, and I will be your conference facilitator. I would like to welcome everyone to the Cara Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Update Conference Call. All lines have been placed on mute to avoid any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star and the number one one on your telephone keypad. Please be advised that this call is being recorded. I would now like to introduce Matt Murphy, Cara's Manager of Investor Relations. Mr. Murphy, you may begin your call. Thank you, operator. Good afternoon. Just after market close today, Cara issued a news release announcing the company's results for the fourth quarter and full year 2022. Copies of this news release and the associated SEC filing can be found in the investor section of our website at www.caratherapeutics.com. Before we begin, let me remind you that during the course of this conference call, we will be making certain forward-looking statements about Cara and our programs based on management's current plans and expectations. These statements are being made under the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties. Actual results may differ materially due to various factors, and Cara undertakes no obligation to update or revise these statements publicly as a result of new information or future results or developments. Investors should read the risk factors set forth in Cara's Form 10-K for the year ended December 31st, 2022, and any subsequent reports filed with the SEC. With that said, I'd like to turn the call over to Chris Posner, Cara's Chief Executive Officer. Chris? Thanks, Matt. Good afternoon, everyone. With me today are Ryan Maynard, our Chief Financial Officer, and Dr. Joana Goncalves, our Chief Medical Officer. I wanna give a quick overview of 2022 and our significant progress executing our strategy to become the world leader in the treatment of chronic pruritus. I will share the latest insights into the KORSUVA injection launch and the progress in our development programs for oral difelikefalin. Ryan will follow with a financial update. After that, we will be available to take your questions. The U.S. launch of KORSUVA injection in the second quarter of 2022 rang in a new era for the treatment of chronic pruritus and propelled Cara forward in our journey to be the category-defining leader in this condition, Chronic pruritus is often a severe, intractable problem for patients in a wide range of diseases. It is underserved by currently used treatments. In light of this lack of treatment options, chronic pruritus remains underreported, even though it can have a significant negative impact on the quality of life of millions of patients. We are committed to enhancing the awareness of this disease and improving the treatment protocols for patient care so that our novel science benefits the most patients possible. Over the past year, we have made great strides in translating our mission into action and firmly establishing our two core franchises in nephrology and dermatology. The launch of KORSUVA injection created the foundation for our nephrology franchise. Together with our commercial partner, CSL Vifor, we are laser-focused on driving the trial and adoption in the U.S. and in countries around the world. We are expanding this differentiated and promising nephrology franchise with oral difelikefalin and the late-stage program in non-dialysis-dependent CKD patients. Enrollment is progressing well, we continue to target the top-line data release for the second half of 2024. Switching to our dermatology franchise, enrollment in our late-stage atopic dermatitis program is progressing well, we continue to track to our internal readout in the second half of 2023. The positive phase II results of oral difelikefalin in notalgia paresthetica not only confirmed our hypothesis that difelikefalin can target pruritus independent of the origin of itch, but also created a distinct opportunity to complement our program in AD. This gives us a unique one-two punch to build a truly one-of-a-kind dermatology franchise. We are excited about the launch of our phase II, III program in NP and the recognition from the New England Journal of Medicine, which recently published our phase II results. Now let me provide some more details on the quarter and the progress within the strategic priorities of our two franchises. First, on the launch of KORSUVA injection, we are making meaningful progress in the U.S. For the fourth quarter of 2022, net sales for KORSUVA injection were $2.3 million, translating into $1.1 million of profit recorded as revenue to us. Wholesaler shipments to dialysis clinics totaled approximately 21,000 vials. This quarterly performance is reflective of the unique launch dynamics in this ecosystem and represents a transition from the stocking and trial phase to the adoption and demand-based performance phase. After the initial inventory building at both the wholesaler and certain clinics in the second and third quarter, we have started to see inventory being drawn down and orders accelerating. We are pleased to see this momentum continuing through the first two months of 2023. Equally as important, feedback on KORSUVA from providers and patients has been highly positive. We continue to hear that KORSUVA is delivering on the promise it demonstrated in the clinical studies and performing as we expected. Let me break out the different dynamics at the various DOs, starting with Fresenius. We are pleased with the commitment from FMC to the long-term success of KORSUVA, as reflected by both the addition of the FMC field force in the promotion of KORSUVA and the push for its rapid adoption. In the third quarter, with patient care as their number one priority, Fresenius took a nontraditional approach and stocked product in most of its clinics to facilitate trial across its network. While this strategy demonstrates FMC's belief in the unmet medical need in CKD-associated pruritus and confidence in KORSUVA's value proposition, it created an atypical inventory dynamic. In the fourth quarter, we saw steady growth in the number of FMC clinics utilizing their initial inventory and placing reorders, a clear reflection of their move from trial to adoption. Simply put, and what is very encouraging, when clinics start using KORSUVA, there is a strong buy-in, and these clinics become repeat customers. This positive trend has accelerated in 2023. Encouragingly, during the first eight weeks of this year, clinic reorders from the wholesalers have already exceeded the entire FMC order volume in the fourth quarter of 2022. Looking ahead, we expect to see continued growth in the number of FMC clinics utilizing their inventory and reordering. As trial shifts to adoption across the FMC network, we expect most of the inventory at the clinic level will be utilized by mid-2023. At DaVita, we see steady growth in the number of clinics ordering KORSUVA. For those clinics that have purchased KORSUVA, we continue to see a high reorder rate, which clearly suggests a positive experience with this product. We continue to work with CSL Vifor on top-down and bottom-up initiatives to accelerate the adoption of KORSUVA at DaVita Clinics. On the MDO and IDO front, uptake continues to be strong, both in terms of the number of clinics ordering as well as the reorder rates. While this segment of the market represents less than 20%, we feel that the progress at these organizations underscores the positive experience of patients and providers with KORSUVA. To summarize, given the launch and inventory dynamics during the first few quarters, we expect a more normal uptake curve for KORSUVA to emerge mid-2023. More specifically, we anticipate that the future sales and vials shipped to dialysis clinics will not be related to any significant stocking at the wholesaler or clinic level. However, until the remaining inventory at the clinic level is depleted, it is important to emphasize that it is the combination of inventory drawdowns at the clinics and new wholesaler shipments to clinics that together represent true patient demand. Overall, we are encouraged by the progress in the U.S. launch, and we remain confident in the long-term potential of KORSUVA. On the international front, the rollout of Kapruvia in Europe continues to gain momentum. Launches in the first four countries, Austria, Germany, Sweden, and Denmark, are progressing well, and we expect most of the other countries in Europe to come online in 2023. The initial feedback is very encouraging and in line with the provider and patient testimonials we have received in the U.S. All four of the Access Consortium countries, Canada, Australia, Singapore, and Switzerland, approved the product in 2022, and we expect launches in these countries to commence once reimbursement is secured in the next 12-18 months. Based on the regulatory submission in the second half of 2022 and positive interactions with the PMDA, we continue to expect a regulatory decision in Japan in the second half of 2023. As a reminder, if the product is approved in Japan, we will receive a milestone payment from our partner, Maruishi. The JV of CSL Vifor and FMC also recently announced signing a long-term exclusive licensing agreement for the co-development and commercialization of KORSUVA with WinHealth in China. We are very excited by this positive development, and we look forward to work starting in the near term. Lastly, let me briefly touch on TDAPA. In the second quarter of 2022, as part of the proposed rule for the calendar year 2023, CMS issued an RFI regarding an appropriate payment mechanism for drugs with TDAPA designation post the TDAPA period. We generally believe that the different payment mechanisms outlined in the RFI would provide adequate reimbursement for KORSUVA post the expiration of its TDAPA period. We further support the concept of linking drug payment to drug utilization in appropriate patients. We continue to work closely with other stakeholders to support CMS in its decision-making process. While we do not have clear visibility as to the exact timing of a final decision regarding the post-TDAPA reimbursement mechanism. We continue to hope for a substantive and positive update from CMS during this year's rulemaking cycle. Moving on to our pipeline. We are building two therapeutic franchises through our work to expand the utility of difelikefalin. Last year, we launched our phase III programs of oral difelikefalin in both pruritus associated with non-dialysis dependent advanced CKD, as well as atopic dermatitis. Enrollment in both programs is progressing well and we expect top line results for the CKD program in the second half of 2024 and for the AD program in the first half of 2025. We continue to track to the second half of 2023 for the internal readout of Part A of the phase III KIND 1 study. Last year we reported positive data from our phase II trial of oral difelikefalin in notalgia paresthetica. In the fourth quarter of 2022, we had a positive interaction with the FDA which cleared the path to initiating our phase II/III program in NP. Like our AD program, we designed the NP program with the goal to enhance our operational efficiency to advance the studies as rapidly as possible and to maximize the potential for success. We expect the internal readout of the dose finding portion of the KOURAGE 1 study in the second half of 2024, with final top line results for the program in the first half of 2026. We believe 2022 was a pivotal year for Cara. Our progress laid the foundation for sustained growth and value creation for our stakeholders and the promising future of our company. On the KORSUVA injection launch, we expected variability and a fluctuating dynamic over the first year of launch. We are seeing positive trends in product uptake and remain confident in the long term potential of KORSUVA injection. We have three late-stage programs underway demonstrating significant progress toward establishing our two therapeutic franchises and maximizing the potential of difelikefalin. I would now like to turn it over to Ryan for additional details on our fourth quarter and full year results. Over to you, Ryan. Thank you, Chris. While I'll be focusing my commentary primarily around the fourth quarter, the full year results for 2022 can be found in our press release issued today after the market closed. Total revenue was $3.3 million for the three months ended December 31st, 2022, compared to $0.8 million for the same period in 2021. Revenue this quarter consisted of $1.1 million of collaborative revenue related to our profit from CSL Vifor's net sales of KORSUVA injection to third parties and $2.1 million of commercial supply revenue. We also recognized $72,000 of royalty revenue this quarter, representing our royalties from the net sales of Kapruvia in Europe in the fourth quarter of 2022. I also want to highlight that for the year we have now recognized a total of $16.6 million of collaborative revenue related to our share of the profit of KORSUVA injection sales. Cost of goods sold during the three months ended December 31st, 2022, was $2.1 million and relates to our commercial supply shipments of KORSUVA injection to CSL Vifor. Research and development expenses were $26 million for the three months ended December 31st, 2022, compared to $22.8 million in the same period of 2021. The increase in R&D expenses is due to the increased clinical trial spend related to our two phase III clinical programs that were initiated in 2022. General and administrative expenses were $6.4 million for the three months ended December 30th, 2022, compared to $11.5 million in the same period of 2021. The reduction in G&A expense was due to a decrease in stock-based compensation in the fourth quarter of 2022 as compared to the same period in 2021. Stock-based compensation in 2021 included costs related to the modification of certain equity awards to our former CEO. Cash, cash equivalents and marketable securities at December 31st, 2022 totaled $156.7 million compared to $236.8 million at December 31st, 2021. The decrease in the balance primarily resulted from cash used in our operating activities. Now we expect that our current unrestricted cash and cash equivalents and available for sale marketable securities are sufficient to fund our currently anticipated operating plan into at least the first half of 2024. This guidance assumes all the spend related to our three late stage clinical development programs and KORSUVA revenue profit share contribution. I will now turn the call back over to Chris. Thanks, Ryan. I want to again emphasize how confident we are in the year ahead, given the momentum of the KORSUVA launch and the significant progress in our pipeline. We believe that Cara is well on its way to becoming the world leader in the treatment of chronic pruritus and we look forward to providing you additional updates in the near term. With that, Ryan, Jo and I will be happy to take your questions so I could turn it back over to Josh and we can open up the call for questions. Thank you. As a reminder to ask a question, please press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Our first question comes from Sumant Kulkarni with Canaccord Genuity. You may proceed. Good afternoon. Thanks for taking my questions. I have two. Given the significant volatility associated with KORSUVA and the way the supply chain dynamics work, could you give us roughly what percent of the 207K vials or so that were shipped during the 2022 year might have already been used? Do you have a fraction on that? Hey, Sumant, it's Chris. Of the 207, I mean, what we look at is we have 20,000 vials that were ordered by the clinics in the Q4 of 2022. What I could tell you is roughly 180,000 of those vials were shipped to Fresenius in Q3 as we reported in the Q3 call. Right. Any sense of how that might translate to actual patient vials used during the year? Yeah. If you look at, if you break it out by customer segment, so if you look at Fresenius first, Fresenius over the first three quarters, you know, Fresenius primarily took in 180,000 vials in Q3, and now they're obviously a lot of clinics are starting to pull through that, you know, burning through that inventory and utilizing that. You also remember there are other segments, namely DaVita and the midsize, that are ordering in a more traditional way. Fresenius did a very atypical thing in terms of stocking. What we expect is probably by mid 2023, you would start to see a more normal, I call it more normal demand-based trajectory. Got it. Then a question on the TDAPA part. We understand that CMS currently requires, you know, reporting on the percentage of a vial that has been unused. What do you think that data might be able to be used for, if at all? Sumant, if your question is wastage of a vial, based on dry body waste? Yes. Is that your question? I wanna make sure I understand it right. That's right. I understand that data needs to be collected or is stored somewhere. Do you foresee any potential use of that data? No. Anywhere, or is that just a procedural thing? That is a procedural thing. Got it. Thank you. You're welcome, Sumant. Thank you. Our next question comes from Joseph Stringer with Needham & Company. You may proceed. Hi. Thanks for taking our question. Was just curious if there's a point in the future where you would be able to report, IV KORSUVA Trx or scripts written instead of, files shipped? Hey, Joe, it's Chris. No is the short answer. You know, think about this as almost like a part B type drug. We get data from, you know, the wholesalers of what they ship to the clinics. You know, typically, Joe, as we've talked about before, this does represent the best proxy for demand because we do know that clinics don't typically hold inventory unless they have a patient already on the product. You know, as I mentioned, this case is very different given this unique ecosystem that we're in, namely with Fresenius, where, you know, they in Q3 took on a significant amount of product to activate their entire network, they invested in that strategy. You know, like I said before, by mid 2023, especially on the Fresenius side, you know, that metric, that quantitative metric that we report, it's unusual right now, but it'll be really the best proxy for patient demand as we get to mid 2023 for Fresenius. The rest, you know, DaVita and the midsize and independents, it's still the best proxy for demand because we know they did not employ the same strategy FMC did in activating their network. It's more traditional. Got it. Thanks for the color, and thanks for taking our question. Thanks, Joe. Thank you. Our next question comes from Annabel Samimy with Stifel. You may proceed. Hi, thanks for taking my question. Just going back to the timing of Fresenius getting through their inventory. I guess, what gives you confidence that it's gonna be out, their inventory is gonna be used up by mid 2023? Are you getting, I guess you must have some order rates from them or reorder rates from them. Is there an sense you can give us of what their reorder rates might be? Are we gonna be getting any more granularity on that going forward? I guess the second question is, just now that patients have been on for a little bit longer, I know the KOL that you had at your Capital Markets Day had discussed some patients, being on therapy, persistently and others taking drug holidays. Are you seeing any more of a pattern there, in how patients are using the treatment? Thanks. Hey, Annabel Samimy. I'll address maybe the second one, but maybe I'll have Jo speak from a medical standpoint. The first one in terms of our confidence in Fresenius and the drawdown of their inventory, let me. As I look at Fresenius, you know, their medical office really understands the effectiveness of this drug and its impact on patients. I mentioned in my prepared remarks, patient care is their number one priority. They employed this really atypical strategy to facilitate trial and adoption, which gives us confidence is that in Q4, many of their clinics in their network are indeed utilizing the product. A number of these clinics have started to reorder. What's really encouraging is when clinics start using KORSUVA, there's a strong buy-in. What we've seen, Annabel Samimy, is that the trends were very encouraging as we exited Q4 of 2022, and they've accelerated in Q1, and we see that in their reorders. We'll constantly track that, but, you know, those trends give us a lot of confidence that by midyear, a lot of that inventory would have been drawn down at the clinic level. Now on persistence, you know, overall from a quantitative standpoint, I'll tell you it's still a little early. We're hearing, you know, again, I mentioned in my prepared remarks, we're hearing very encouraging remarks from patients and providers. I also look at, n ow I'm a quantitative guy, I look at the proof point around reorder rates, and the majority of the clinics that start a patient on KORSUVA reorder. There's a strong buy-in. We see very high reorder rates, which to me is the metric for satisfaction from a provider and patient. Medically, Jo, turn it to you. Thanks, Annabel. Just as a reminder, you know, our label is for chronic pruritus, and the drug needs to be given daily as it was conducted in our clinical studies. As you recall, our clinical studies had pretty good continued use of the drug over time. You know, that is what we expect to see. As Chris mentioned, we haven't really seen anything differently really to date. Okay. Great. Thank you. Thank you. Our next question comes from David Amsellem with Piper Sandler. You may proceed. Thanks. In just in looking at your cash runway guidance that gets you into the first half of 2024, I'm just trying to do some basic math here. I guess what I'm sort of coming to, just wanted to run this by you, is that you're Given the level of R&D spend, with all the clinical programs going on for oral DFK, it would sort of imply that a pretty modest sales number and pro-net profit number for KORSUVA injection for 2023. I mean, I'm not saying that it wouldn't imply growth, but it's still pretty modest. I guess, is that the right way to think about it? If it is, then the question is, how is it just inventory that's really explaining what's happening here? In other words, are you caught off guard by where demand is relative to perhaps where you thought it might be ahead of the launch? Just wanted to get a sense of your thought process there and is my basic thinking about it correct? Thank you. Hi, David. Thanks for the question. This is Ryan. A couple things on the runway guidance. First of all, it's consistent with the guidance that was given at the end of Q3, so that was as well first half of 2024. You're correct, the expectation that is in this very conservative guidance is definitely a conservative haircut, both on our own internal projections as well as the projections of our partner. We're still in the first year of launch. I wanted to be consistent on this guidance, but I wouldn't look into anything on that math that you're doing as it relates to our expectations for KORSUVA. As far as your second question on I'll pass that to Chris. Yeah. David, on your second question, I mean, you know, we expected variability. I mean, we're within the first year of launch and this is a unique dialysis patient ecosystem. We did expect some variability. you know, we'll be truthful here in that, you know, what was surprising was FMC's Q3 strategy with that large purchase, as we mentioned on the Q3 call. I think I'd use the word pleasantly surprised too, 'cause, you know, this strategy, what they invested in was to activate their entire network. It certainly shows their commitment, and I do know that their executive team is fully committed to getting this product to patients that are appropriate for it. That was the surprising part, but, you know, what's really important to point out is that we're seeing the fruits of that now. We're seeing the acceleration, you know, as we exited Q4, and we're actually seeing it accelerate even more in the first eight weeks of Q1. It's actually nearly double than what we saw in coming out of Q4. We're actually quite, we're quite confident in terms of the future performance of this drug. If I may just follow up. Is it something where we should be at all concerned about the magnitude of the inventory drawdown? I mean, in other words, I guess I'll ask the question differently. If demand was indeed robust, would we have seen a this kind of magnitude of inventory drawdown? Well, I mean, so the question, maybe I'll phrase it a little differently, if you don't mind. Sure. Would we have expected this to burn down quicker in Q4, essentially, right? I mean, that's kinda what you're asking, is this one a time in a way, right? You know, what I'd say to that, David, is that, you know, we are building a market from scratch. This market has many stakeholders, as you know, right? The in-clinic dialysis care teams, nephrologists, and their, you know, affiliated nurses, and patients. I will tell you, CSL Vifor and their JV partner, Fresenius namely, have done a really strong job at working the elements of the dialysis patient ecosystem. You know, while all this is happening, you gotta remember there's, and I'll speak to Fresenius, there's 2,600 plus clinics in Fresenius, and they all have different characteristics in terms of staffing, how they adopt a product. Some tend to be a little in front of others or a little behind others. Bottom line is, I will say the FMC suite is putting product on the shelves, and they're making it available to get it used. The trends are really encouraging towards the end of Q4, and they've accelerated in Q1. I think it's one of time, and we're seeing really, really positive trends coming out of Q4, and these first eight weeks of Q1 give us even more confidence as we progress forward. Okay. Thank you. You got it, David. Thank you. Our next question comes from AJ Velasquez-Mao with Jefferies. You may proceed. Hi, you all. This is AJ for Chris. You mentioned that you're still seeing more clinics come online and that reorder rates are growing. Could you give us either an order of magnitude on those rates or some kind of% capture? Hey, AJ, it's Chris. What I can say is the first eight weeks, and we said this in the prepared remarks, are certainly more than all of Q4. Won't give a range yet, but I will say also on Fresenius namely, and we look very closely at Fresenius in terms of them pulling through, you know, the first eight weeks of this year, is significantly more than the eight weeks ending December 30, 2022. We're really encouraged with those trends. Okay. I have one kind of follow-up question. I feel like it's been a while since you've mentioned the NKF educational campaign. Do you have any visibility on what kinds of engagements you're getting there in terms of awareness or advocacy? Yeah. It's actually, the NKF is just one of a couple campaigns out there right now. You know, the KPIs that we look at are very positive. If you look at the awareness numbers among the providers, it's very high. And what we're seeing from a patient standpoint is very good advocacy building at the patient from the patients. You know, CSL Vifor is partnered with most of the patient advocacy groups. Programs are initiated to raise the awareness. I mentioned, you know, one of the things, AJ, and I think you and I spoke about this before, that's a critical lever in terms of, you know, driving the trajectory of KORSUVA injection. You know, I look at multiple stakeholders in terms of, you know, in dialysis clinic care teams, dialysis care teams, nephrologists and patients, CSL Vifor has done a very, very good job across the board on each of those levers. I think that's why you're seeing this acceleration in demand following the purchase, the large purchase from Fresenius in Q3. Gotcha. Thanks, Chris. You got it. Thank you. Our next question comes from Oren Livnat with H.C. Wainwright. You may proceed. Thanks. I'm gonna keep along the same track as most people are asking, you know, for obvious reasons. You know, this inventory work through at the high level isn't totally surprising to me, but of course, we're all just trying to figure out some way to gauge or to understand what your level of understanding is around the demand side of this equation, right? What information do you get from CSL with regards to volume, including what's still sitting at the wholesaler in terms of vials, maybe what's sitting at the center level, which that sounds more difficult to ascertain, and/or just prescription levels? Obviously we can say, "Hey, the first half of this year we're gonna keep working through." If we don't know how much is there to begin with, how much we're working through, and what the underlying pull-through demand is, we have no idea what the exit rate is come mid-2023, right? Any help you can give us there with, you know, clarity, and then I have a follow-up. Sure, Oren. I mean, we committed to providing two metrics, right? Net sales, that's shipments from CSL to the wholesaler. Then we committed to orders being, well, orders from the dialysis clinics from the wholesalers. Those are the critical metrics. We have visibility into what's at the wholesaler, we have visibility to what clinics order. You're right. What's hard is the visibility at the clinic level from the stocking. You know, to your question, as you model this, as we think about this, we think about this with our partner, we look very closely, and I'm gonna speak specifically to Fresenius, we look very closely at the orders, the reorder rate from Fresenius. What gives us a lot of confidence is that we are seeing that accelerate in Q4, we're seeing that even quickly or more quicker accelerate in the 1st eight weeks of Q1. That's why we're saying, you know, we, you know, we're encouraged with those trends, and that's why we think probably by mid-year the inventory will have been pretty much drawn down at those clinic levels. We would expect the reorder rates to continue to accelerate as we move forward through the 1st quarter and 2nd quarter of this year. We have good visibility. You know, you mentioned also prescriptions. I mean, we don't get that data, obviously. Like I mentioned earlier on the call, you know, this is a, you know, this is a buy and bill sort of market in a way. We look at orders. Yeah, I think that was the last part of your question. I mean, someone knows how many boxes or vials are still sitting at the wholesaler per an inventory management agreement, I would assume, right? Of course. Of course. Okay. You won't tell us that. What Well, no, I mean, but Oren, what's really important is that we said by mid 2023, we expect what I call a more demand-based trajectory. Understood. Meaning demand will drive shipments from the wholesalers. They'll converge. You know, right now we have to work down the inventory of Fresenius. You know, I view the Fresenius thing as a real positive. You know, they took this very atypical approach because they believe in the product and believe in helping their patients, and they really wanna make this available across their network. They invested significant time and dollars in this. You know, that was in Q3. Now we're seeing that drive-through in Q4, and we're seeing that accelerate in the first part of Q1. Understood. Also on those 21,000 vials that were ordered this quarter on top of, you know, inventory being worked through, can you characterize who ordered those? I mean, I think you said there were reorders from Fresenius centers. Can you give us any mix on where those went? Yeah. I would say the $20,000 or $21,000, you know, obviously it's a combination of reorders from Fresenius and also, you know, we have two other customer segments, right? We have DaVita, and then we have the midsize and independent. I would say Q4 is probably closer to 50/50. Okay. That's helpful. Just lastly, if I may, on the post-TDAPA bundling decision, I understand you're still hoping to hear something substantive this fall, it sounds like. Regardless of what that outcome is in terms of what methodology they use, do you have an idea on when the timing of that should kick in? Because I guess we don't, we only have an N-of- 1, right, to go on, and they got three years. It looks like your two-year anniversary of your approval at least sort of takes you already, you know, a third of the way or more into 2024 in, you know, into year three. Is it do you think there's a good chance you're gonna have TDAPA pricing through 2024? Yeah, we don't I'm not gonna put a, you know, a probability on that, but I think you got the timing right. I mean, TDAPA expires at the end of March 2024, you know, unless we get a third year. I think what's also really important to point out is exactly what you pointed out, is that, you know, we have been working with CMS, you know, with our partner CSL Vifor for, and other stakeholders around the post-TDAPA funding designation and making that, you know, working with CMS to change that appropriately to get it outside the bundle to have an innovative product available for patients afterwards. You know, we're encouraged at where we are with CMS. Yeah, I don't have a probability I could give you on the third year. There is an N -of- 1. It's certainly something that we would be with our partner CSL Vifor talking about at some point. Right now the focus is on working with CMS on changing the policy. Got it. Thanks for the help. Appreciate it. All right, Oren. Thank you. As a reminder, to ask a question, you'll need to press star one one on your telephone. Our next question comes from Jason Gerberry with Bank of America. You may proceed. Hey, guys. Thanks for taking my questions. Just thinking about the TDAPA piece a little bit more, you know, how important is it that you build up a more material volume level to generate good pharmacoeconomic argument for the pricing levels that, you know, have been so far established during the TDAPA window? I think to what, you know, Oren was getting at, you know, your TDAPA could run out in April 2024 with your cash runway to first half 2024. So it seems like it's a really critical aspect of the longevity of this, you know, launch for the IV. Are there any milestones you anticipate realizing in 2023? Hey, Jason, it's Chris. I'll tackle each of those. I'll go in order. How about that and make it easy? Yep. Your first question on urgency around utilization, you know, I would say as a commercial guy at heart, I mean, regardless of TDAPA, there's always a lot of urgency in getting a product to patients as fast as possible. I do agree with you though that TDAPA, you know, heightens that sense of urgency, I'd also remind you we're still within the first year of launch. You know, I know CSL Vifor and their JV partner Fresenius has every inclination, and we see these very encouraging trends that I'm encouraged throughout the year that this is going to be a really, really good trajectory that we're gonna see in terms of utilization. The second question was around how important is TDAPA and when it expires the durability of the sales. You know, I've always said, you know, I've been at the helm for a little over a year, and I've always said that I still, regardless of funding and et cetera. You know, this product will be available if TDAPA continues, and I do believe strongly in the durability of this drug. Unlike the analog Parsabiv, where there are alternatives, namely a generic oral Sensipar, there are no alternatives. We are the first and only FDA-approved drug. I would find it highly odd that if patients are on therapy, that they would be removed from therapy, you know, and given back to a, you know, a non-standard antihistamine, that certainly has limited in terms of efficacy and safety. I still feel very strongly in the durability, but I'm also, you know, quite pleased with the efforts from both companies, Cara and CSL Vifor, in terms of moving the needle on CMS. I think CMS has a real open mind to look at the post TDAPA payment mechanisms. We'll see how that plays out throughout the year. Your last one, any milestones. Yeah, we would expect a Japanese milestone pending approval that we would expect in the second half of this year. Got it. Okay. Thanks, guys. Thanks, Jason. Thank you. Our next question comes from Oren Livnat with H.C. Wainwright. You may proceed. Sorry. Just had one follow-up on guidance. No problem. You know. Yeah. I understand historically you've been quite conservative on that front. I think last update in November, which was still for a, you know, first half 2024 runway, that was based on, I think you said, you know, if we just flatlined the current product run rate and spend what we think we're gonna spend, we would make the first half of 2024. Of course, you expected the product to grow. Now, it sounds like maybe in your answer to, I think it was David's question, you put it a little differently, which is, you know, based on our internal projections. I mean, clearly you're not basing it on this quarter's run rate of sales because it's, you know, artificially depressed, right? I guess I'm trying to figure out is, in your guidance, are you projecting, I guess, a more traditional ramp through the year, and that's how you get there? Is it still like, look, if we went back to sort of an underlying demand number that we think we were at this quarter and flatlined that's our still quite conservative guidance. Does that make sense? Oren, perfect sense. This is Ryan again. I think the way to think about it, and you're correct on kind of the transition of the guidance from Q3 to Q2 to Q3 and where we are now. I would say that the very conservative number that we have in this runway guidance, as I mentioned, is a haircut to our internal projections for KORSUVA, which as Chris mentioned, we are very, very positive about and positive about the full year. I've kept it at the first half of 2024, but you've also noticed that I said at least into the first half of 2024. The biggest driver and the biggest variable to this is KORSUVA profit share. I've haircut what our internal projections. It's also important, we've talked about this before, and as we, at some point, want to give guidance along with our partner, CSL Vifor, on what our true expectations are for the drug. We're still in the first year of launch. As we've said over and over again, there's variability, and I've tried to stay ultra-conservative in my cash runway forecast just for that purpose. That doesn't, y ou know, using math to back into what our expectations are using my runway forecast is not accurate because that is haircut substantially from what we believe for- We can't back into either the spend or the revenue. Correct. Gotcha. All right, thanks. Appreciate it. Thank you. Our next question comes from Sumant Kulkarni with Canaccord Genuity. You may proceed. Thanks for the follow-up. My question is on TDAPA. What's the specific metric used by TDAPA to calculate the utilization rate? How much visibility does Cara have on that variable on a real-time basis, if at all? Hey, Sumant, it's Chris. What they do is look at claims data. You know, again, I can just take you through what they did with Parsabiv, right? They looked at claims data on the number of units of Parsabiv and then multiplied that by their ASP. For Parsabiv, they obviously added in the units for the generic and the branded oral Sensipar, multiplied it by their ASP and divided it by the number of total dialysis treatments, and they arrived at roughly $10 a session or roughly, you know, let's say, you know, $700 million total for the bundle. We don't have real-time, neither does CSL. We don't have real-time utilization data that CMS has. Based off of that kind of dynamic, what do you think the sweet spot would be to calculate that to arrive at a TDAPA kind of reimbursement? Would that be at some point, you know, later this year, next year? Well- How should we think about that? Yeah. Suman, again, I would say, I mean, what CMS wants to look at, I mean, looking at their current rule and forget I'm gonna, I'm gonna, you know, piece off of all that work we're doing on changing the post TDAPA mechanism, which is actually pretty encouraging. I'll go back to their current kinda rule, is that they want to look at year years of utilization. There's 1 comp, and that's Parsabiv. As I mentioned before, the reason they got a 3rd year was they said, you know, they said roughly that, "Hey, the 1st 6 months or so of a launch, given that it's six months in arrears, is probably not a real stable environment 'cause you're." Just like our launch, right? There's interesting dynamics. You're building. There's some inventory. It's not a true reflection of utilization. That's why they got the third year. To the answer to your question, I would say later next year, at the end of next year, probably the end of 2024 would be the best time to kind of calculate to see what sort of funding would be required for KORSUVA. just the last one on those lines. Is this instability or volatility in demand an advantage or a disadvantage when it comes to a TDAPA extension? Well, you know, again, I can only look at what Parsabiv, they used it as an advantage to get a third year, right? Saying the first six months of a launch or, you know, it's not steady state. That's, again, I would say more of a personal opinion. I mean, I don't have many data points to look at other than that. Got it. Thank you. Thank you. This concludes the Q&A session. I'd now like to turn the call back over to Chris for any closing remarks. I'd like to thank everyone for joining us this afternoon. We look forward to providing updates in the coming quarter. Thank you very much.